‘There is simply too much medicine in Psychiatry.’ Critically evaluate this claim.

Critics argue that the broad criteria for psychiatric diagnoses can lead to overdiagnosis and consequently, unnecessary medication (Merten et al., 2017). For instance, everyday experiences like grief or stress might be diagnosed as depression or anxiety disorder, leading to prescription of medication when other interventions, like behavioural therapy for example, could suffice (Ian Freckelton, 2018). There are concerns about over-prescription of psychiatric medication, especially to children and adolescents (Hales et al., 2018).

Nonetheless, for many individuals, psychiatric medication is crucial and can significantly improve quality of life. Conditions like schizophrenia, bipolar disorder, or severe depression may necessitate medication for symptom control (Kamenov et al., 2017; Leichsenring et al., 2022).

The claim that there is "too much medicine in psychiatry" can be understood from different perspectives and is a subject of considerable debate. We will explore the arguments both for and against this statement.

Some suggest that psychiatry tends to pathologize normal variations in behaviour, leading to the unnecessary use of medications (Frances, n.d.). Some people suffer with anxiety after a loss or stressful event. This is a normal and healthy response (Grief, n.d.; NIMH » Anxiety Disorders, n.d.). However, according to some critics, psychiatry may pathologize this normal reaction by labelling it as depression or anxiety disorder (Sweet & Decoteau, 2018). Restlessness in children for example has been increasingly categorized as attention deficit hyperactivity disorder (ADHD), with stimulant medications being prescribed (Connor, 2011; Moreira-Maia et al., 2018). The diagnosis of ADHD has received a lot of attention. Some critics argue that the criteria for ADHD are too broad and that many children who are

diagnosed with ADHD are simply behaving in ways that are normal for their age and developmental stage (Honkasilta & Koutsoklenis, 2022). The pathologizing of normal behaviour can lead to several negative consequences. One concern is that it can lead to the unnecessary use of medications. For example, a child who is diagnosed with ADHD may be prescribed stimulant medications, even though they may not need them. Stimulant medications can have serious side effects, such as insomnia, anxiety, and decreased appetite (Merten et al., 2017). Critics argue that some individuals are diagnosed with mental disorders and prescribed medication when the may not meet the clinical criteria for diagnosis. This overdiagnosis can lead to unnecessary medication use, potentially exposing patients to side effects associated with psychiatric drugs (Merten et al., 2017; Thombs et al., 2019).

On the opposing side of the argument, it is suggested that rather than excessively diagnosing individuals who may not require it, the medical profession may be failing to accurately diagnose a substantial number of individuals who do require it (Stolzenburg et al., 2019). It is estimated that three in four people that take anti-depressants do not have a depression, but three in four people that do actually have clinical depression get no medication at all (British Medical Journal, 2017). The question of when a particular ‘state of mind’ should be classified as a mental health problem is a complex one involving many different factors.

Another argument is that overmedication can contribute to the stigmatization of mental health conditions (Rössler, 2016). Stigmatization in mental health refers to the negative attitudes, stereotypes, and discriminatory behaviours directed toward individuals who have mental health conditions. It is a pervasive issue that can have serious consequences for those affected (*Stigma and Discrimination | Mental Health Foundation*, n.d.).

When everyday emotions and experiences are pathologized and medicated, it may reinforce the idea that these conditions are inherently abnormal, which can lead to further stigma and

discrimination (The Lancet, 2022). Stigmatization often discourages individuals from seeking help for mental health issues. Fear of judgment or discrimination can lead to delayed or inadequate treatment, which can worsen the condition (Corrigan et al., 2012).

In order to reduce that stigma, public education campaigns can help dispel myths and increase understanding of mental health conditions. Promoting open dialogue about mental health can reduce stigma (Norms et al., 2016). There are various organizations and initiatives work to reduce stigma. These programs aim to challenge stereotypes and promote acceptance.

Addressing stigmatization in mental health is essential to creating a more inclusive and supportive society for individuals living with mental health conditions. It requires a collective effort involving individuals, communities, healthcare providers, policymakers, and organizations to promote understanding, empathy, and equal treatment for all.

There is also a claim that pharmaceutical companies have heavily marketed psychiatric drugs, potentially leading to overuse driven by profit motives rather than patient need (Sharfstein, 2005). The claim is that pharmaceutical companies have heavily marketed psychiatric drugs, leading to potential overuse driven by profit motives rather than patient need (Davari et al., 2018). Critics argue disease awareness campaigns sponsored by drug companies overstate the prevalence of conditions like depression and anxiety to expand the market for medications to treat them (Migone, 2017). Pharmaceutical companies are profit-driven organizations, and the sales of psychiatric drugs can be highly lucrative. High demand for these medications can lead to substantial financial gains for these companies. Concerns have been raised about potential conflicts of interest within the medical community, as some healthcare providers, especially in the US, receive financial incentives, gifts, or sponsorship from pharmaceutical companies. These financial ties may influence prescribing decisions. The marketing of psychiatric drugs has raised ethical concerns within the medical community, including

questions about transparency, patient autonomy, and the prioritization of profit over patient well-being (King & Bearman, 2017; Mitchell et al., 2017).

It's important to note that psychiatric medications can be beneficial and even lifesaving for many individuals with mental health conditions. The concern arises when marketing practices prioritize profit motives over patient well-being, potentially leading to the overuse or inappropriate use of these medications. Balancing the need for effective treatments with ethical marketing practices and rigorous oversight is a challenge that continues to be debated and addressed within the healthcare and pharmaceutical industries (Bourcier-Béquaert et al., 2022) . Overall, many argue profit-driven pharmaceutical marketing and lobbying practices encourage inappropriate overmedication, overdiagnosis, and higher than necessary spending on medications (*Spending on Consumer Advertising for Top-Selling Prescription Drugs in U.S. Favors Those With Low Added Benefit | Johns Hopkins | Bloomberg School of Public Health*, n.d.). However, others say marketing provides useful information and we need a balanced approach recognizing pharmaceutical innovation helps many patients (Levy, 1994).

A futher argument concerns the pursuit of and predilection for fast remedies over taking into account adverse repercussions and long-term implications. In a fast-paced society, many individuals seek rapid relief from distressing mental health symptoms. Quick-fix solutions, such as psychiatric medications, can offer the allure of immediate relief compared to longer-term therapeutic interventions like psychotherapy, which may require more time and effort (Breggin, 2008; *Unhinged: The Trouble with Psychiatry—A Doctor's Revelations about a Profession in Crisis.*, n.d.). Psychiatric medications are often viewed as effective tools for suppressing or alleviating symptoms. They can offer a sense of relief from acute distress, such as anxiety or depression, without addressing the underlying causes (Cuijpers et al., 2023; Ivanov & Schwartz, 2021). The desire for quick relief may overshadow concerns about potential side effects. Some individuals may be willing to tolerate side effects in the short

term if it means immediate symptom relief. The use of psychiatric medications over the long term can have a range of consequences, including potential side effects, dependency, and the masking of underlying issues (*Advances in Psychiatric Treatment | BJPsych Advances | Cambridge Core*, n.d.). These effects may not become apparent until later in treatment. Clearly, effective mental healthcare should involve shared decision-making between patients and healthcare providers. In some cases, individuals may not be adequately informed about the potential long-term effects of medications, impacting their ability to make informed choices (Mahone et al., 2011). Mental health treatment is most effective when it takes a holistic approach, considering both immediate symptom relief and long-term well-being. This includes addressing the root causes of mental health conditions and exploring a range of therapeutic options (*A Holistic Approach to Mental Health*, n.d.).

For many patients, psychiatric medication can be very helpful in managing conditions like depression, anxiety, bipolar disorder, etc. Used properly, it can improve quality of life.

Psychotherapy alone is not always sufficient treatment. Medication and psychotherapy together is often the most effective approach. While some over-prescription may occur, psychiatric medicines are generally approved as safe and effective when prescribed and monitored correctly. Mental illness has biological/neurochemical roots that may require medical treatments. Criticisms of medication use may stigmatize those who benefit from it. Medication, when used appropriately, should not be viewed negatively. Overall, while over-prescription is a risk, psychiatric medication plays an important role in treating mental illness for many patients. Careful diagnosis, monitoring of side effects, and integrating medication with psychosocial treatments can help ensure appropriate use. Claims of simply "too much medicine" in psychiatry may be overstated.

In evaluating the claim that there is "too much medicine in psychiatry," it is important to consider both the potential for over-reliance on medication and the genuine need for pharmacological interventions in many cases. A balanced approach would involve judicious use of medication alongside other therapeutic modalities, tailored to the individual needs of the patient. The debate also underscores the importance of continuous research, ethical considerations, and patient-centred care in the field of psychiatry.

Merten, E. C., Cwik, J. C., Margraf, J., & Schneider, S. (2017). Overdiagnosis of mental disorders in children and adolescents (in developed countries). *Child and Adolescent Psychiatry and Mental Health*, *11*(1), 1–11. https://doi.org/10.1186/S13034-016-0140-5/TABLES/1

Ian Freckelton, Q. (2018). Overdiagnosis in Psychiatry: How Modern Psychiatry Lost Its Way While Creating a Diagnosis for Almost All of Life's Misfortunes, by Paris Joel: Oxford University Press, 2015, xi-xix and 1-181 pp., US$50.36 (paperback), ISBN 978-0-19-935064-3. *Psychiatry, Psychology, and Law*, *25*(2), 325. https://doi.org/10.1080/13218719.2018.1463588

Hales, C. M., Kit, B. K., Gu, Q., & Ogden, C. L. (2018). Trends in Prescription Medication Use Among Children and Adolescents—United States, 1999-2014. *JAMA*, *319*(19), 2009–2020. https://doi.org/10.1001/JAMA.2018.5690

Kamenov, K., Twomey, C., Cabello, M., Prina, A. M., & Ayuso-Mateos, J. L. (2017). The efficacy of psychotherapy, pharmacotherapy and their combination on functioning and quality of life in depression: a meta-analysis. *Psychological Medicine*, *47*(3), 414. https://doi.org/10.1017/S0033291716002774

Leichsenring, F., Steinert, C., Rabung, S., & Ioannidis, J. P. A. (2022). The efficacy of psychotherapies and pharmacotherapies for mental disorders in adults: an umbrella review and meta-analytic evaluation of recent meta-analyses. *World Psychiatry*, *21*(1), 133. https://doi.org/10.1002/WPS.20941

Frances, A. (n.d.). Saving Normal : an insider's revolt against out-of-control psychiatric diagnosis, DSM-5, big pharma, and the medicalization of ordinary life. 324

Grief. (n.d.). Retrieved November 12, 2023, from https://www.apa.org/topics/grief/

NIMH » Anxiety Disorders. (n.d.). Retrieved November 12, 2023, from https://www.nimh.nih.gov/health/topics/anxiety-disorders

Sweet, P. L., & Decoteau, C. L. (2018). Contesting normal: The DSM-5 and psychiatric subjectivation. BioSocieties, 13(1), 103–122. https://doi.org/10.1057/S41292-017-0056-1/METRICS

Connor, D. F. (2011). Problems of overdiagnosis and overprescribing in ADHD: are they legitimate? *Psychiatric Times*, *28*(8), 14–14. https://go.gale.com/ps/i.do?p=AONE&sw=w&issn=08932905&v=2.1&it=r&id=GALE%7CA264271228&sid=googleScholar&linkaccess=fulltext

Moreira-Maia, C. R., Massuti, R., Tessari, L., Campani, F., Akutagava-Martins, G. C., Cortese, S., & Rohde, L. A. (2018). Are ADHD medications under or over prescribed worldwide?: Protocol for a systematic review and meta-analysis. *Medicine*, *97*(24). https://doi.org/10.1097/MD.0000000000010923

Honkasilta, J., & Koutsoklenis, A. (2022). The (Un)real Existence of ADHD—Criteria, Functions, and Forms of the Diagnostic Entity. *Frontiers in Sociology*, *7*, 814763. https://doi.org/10.3389/FSOC.2022.814763

Merten, E. C., Cwik, J. C., Margraf, J., & Schneider, S. (2017). Overdiagnosis of mental disorders in children and adolescents (in developed countries). *Child and Adolescent Psychiatry and Mental Health*, *11*(1), 1–11. https://doi.org/10.1186/S13034-016-0140-5/TABLES/1

Thombs, B., Turner, K. A., & Shrier, I. (2019). Defining and Evaluating Overdiagnosis in Mental Health: A Meta-Research Review. *Psychotherapy and Psychosomatics*, *88*(4), 193–202. https://doi.org/10.1159/000501647

Stolzenburg, S., Freitag, S., Evans-Lacko, S., Speerforck, S., Schmidt, S., & Schomerus, G. (2019). Individuals with currently untreated mental illness: causal beliefs and readiness to seek help. *Epidemiology and Psychiatric Sciences*, *28*(4), 446–457. https://doi.org/10.1017/S2045796017000828

Rössler, W. (2016). The stigma of mental disorders: A millennia-long history of social exclusion and prejudices. *EMBO Reports*, *17*(9), 1250. https://doi.org/10.15252/EMBR.201643041

Stigma and discrimination | Mental Health Foundation. (n.d.). Retrieved November 20, 2023, from https://www.mentalhealth.org.uk/explore-mental-health/a-z-topics/stigma-and-discrimination

The Lancet. (2022). Can we end stigma and discrimination in mental health? *The Lancet*, *400*(10361), 1381. https://doi.org/10.1016/S0140-6736(22)01937-7

Corrigan, P. W., Morris, S. B., Michaels, P. J., Rafacz, J. D., & Rüsch, N. (2012). Challenging the public stigma of mental illness: A meta-analysis of outcome studies. Psychiatric Services, 63(10), 963–973. https://doi.org/10.1176/APPI.PS.201100529/ASSET/IMAGES/LARGE/963F1.JPEG

Norms, C. on the S. of C. B. H. S., Board on Behavioral, C. and S. S., Education, D. of B. and S. S. and, & National Academies of Sciences, E. and M. (2016). *Approaches to Reducing Stigma*. https://www.ncbi.nlm.nih.gov/books/NBK384914/

Sharfstein, S. S. (2005). Big Pharma and American Psychiatry: The Good, the Bad, and the Ugly. Https://Doi.Org/10.1176/Pn.40.16.00400003, 40(16), 3–4. https://doi.org/10.1176/PN.40.16.00400003

Davari, M., Khorasani, E., & Tigabu, B. M. (2018). Factors Influencing Prescribing Decisions of Physicians: A Review. *Ethiopian Journal of Health Sciences*, *28*(6), 795. https://doi.org/10.4314/EJHS.V28I6.15

Migone, P. (2017). The influence of pharmaceutical companies. Research in Psychotherapy : Psychopathology, Process, and Outcome, 20(2), 136–138. https://doi.org/10.4081/RIPPPO.2017.276

King, M., & Bearman, P. S. (2017). Gifts and influence: Conflict of interest policies and prescribing of psychotropic medications in the United States. Social Science & Medicine (1982), 172, 153. https://doi.org/10.1016/J.SOCSCIMED.2016.11.010

Mitchell, A. P., Winn, A., & Dusetzina, S. (2017). Pharmaceutical industry payments and oncologist drug selection. Journal of Clinical Oncology, 35(15_suppl), 6510–6510. https://doi.org/10.1200/JCO.2017.35.15_SUPPL.6510

Bourcier-Béquaert, B., Baïada-Hirèche, L., & Sachet-Milliat, A. (2022). Cure or Sell: How Do Pharmaceutical Industry Marketers Combine Their Dual Mission? An Approach Using Moral Dissonance. *Journal of Business Ethics*, *175*(3), 555–581. https://doi.org/10.1007/S10551-020-04657-4/TABLES/8

Spending on Consumer Advertising for Top-Selling Prescription Drugs in U.S. Favors Those With Low Added Benefit | Johns Hopkins | Bloomberg School of Public Health. (n.d.). Retrieved November 20, 2023, from https://publichealth.jhu.edu/2023/spending-on-consumer-advertising-for-top-selling-prescription-drugs-in-us-favors-those-with-low-added-benefit

Levy, R. (1994). The role and value of pharmaceutical marketing. Archives of Family Medicine, 3(4), 327–332. https://doi.org/10.1001/ARCHFAMI.3.4.327

Breggin, P. R. (2008). Medication madness : a psychiatrist exposes the dangers of mood-altering medications. 384. https://search.worldcat.org/title/156832369

Cuijpers, P., Miguel, C., Harrer, M., Plessen, C. Y., Ciharova, M., Papola, D., Ebert, D., & Karyotaki, E. (2023). Psychological treatment of depression: A systematic overview of a 'Meta-Analytic Research Domain.' Journal of Affective Disorders, 335, 141–151. https://doi.org/10.1016/J.JAD.2023.05.011

Ivanov, I., & Schwartz, J. M. (2021). Why Psychotropic Drugs Don't Cure Mental Illness—But Should They? Frontiers in Psychiatry, 12, 579566. https://doi.org/10.3389/FPSYT.2021.579566/BIBTEX

Advances in Psychiatric Treatment | BJPsych Advances | Cambridge Core. (n.d.). Retrieved November 19, 2023, from https://www.cambridge.org/core/journals/bjpsych-advances/information/about-this-journal/past-titles/past-title/advances-in-psychiatric-treatment/information/257BBF18465232AEA2C5A7EA479EF803

Mahone, I. H., Farrell, S., Hinton, I., Johnson, R., Moody, D., Rifkin, K., Moore, K., Becker, M., & Barker, M. R. (2011). Shared Decision Making in Mental Health Treatment: Qualitative Findings from Stakeholder Focus Groups. *Archives of Psychiatric Nursing*, *25*(6), e27. https://doi.org/10.1016/J.APNU.2011.04.003

A Holistic Approach to Mental Health. (n.d.). Retrieved November 20, 2023, from https://onlinedegrees.nku.edu/articles/msn/holistic-approach-to-mental-health.aspx